These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Reduction of amyloid beta by Aβ3-10-KLH vaccine also decreases tau pathology in 3×Tg-AD mice.
    Author: Zhang HY, Zhu K, Meng Y, Ding L, Wang JC, Yin WC, Yan Y, Cao YP.
    Journal: Brain Res Bull; 2018 Sep; 142():233-240. PubMed ID: 30077729.
    Abstract:
    Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive amyloid-β (Aβ) accumulation, neurofibrillary tangles (NFTs) formation and synaptic alterations. Active immunotherapy is regarded as one of the most promising strategies for AD prevention and treatment. In this research, we used APPswe/PS1M146 V/TauP301 L triple transgenic (3×Tg-AD) mice, in which the pathological changes are the most similar to those in AD patients. The Aβ 3-10 -keyhole limpet haemocyanin (KLH) vaccine was administered to mice at 1 month, and no AD-associated changes were detected at that time. The vaccine effectively mitigated AD-like pathology and cognitive dysfunction in the 3×Tg-AD mice. Both soluble and insoluble Aβ and tau protein in the brain tissues of the 3×Tg-AD mice were significantly decreased after the administration of Aβ 3-10 -KLH. In addition, the level of phosphorylated tau also decreased following removal of the Aβ pathological changes.
    [Abstract] [Full Text] [Related] [New Search]